Biolum Sciences

Nanoscope Therapeutics, Inc., based in Dallas, TX, is pioneering a new generation of optogenetic therapies aimed at restoring vision lost to inherited retinal diseases. With a commitment to improving the lives of patients, the company emphasizes compassion and innovation in its mission to bring back hope and independence to those affected by vision loss. Utilizing its advanced multi-characteristic opsin (MCO) platform, Nanoscope has developed MCO-010, the first broad spectrum and ultra-sensitive optogenetic technology capable of restoring vision in patients with severe vision loss. Through its ongoing clinical trials and patient-centered initiatives, the organization continues to drive advancements in therapeutic possibilities for retinal disease. Generated from the website

Dialectic Therapeutics, Inc. is a Dallas-based biotechnology company dedicated to developing innovative anti-cancer therapies aimed at improving the lives of patients with limited treatment options. Founded by esteemed cancer scientists and experienced biotech investors, the company focuses on creating targeted treatments with reduced toxicities through its novel APTaD platform. The company's lead candidate, DT2216, is designed to selectively induce cancer cell death by targeting the BCL-XL protein, demonstrating effectiveness in both liquid and solid tumors with minimal toxicity. With a team comprising experts in protein degradation and clinical development, Dialectic Therapeutics is committed to addressing high unmet needs in late-stage cancer treatment. Generated from the website

Lantern Pharma Inc. is a clinical stage biotechnology company based in Dallas, Texas, dedicated to innovating the cancer drug development process through advanced genomics, machine learning, and artificial intelligence. Their proprietary A.I. platform, RADR, encompasses over 100 billion data points to identify genomic signatures correlated with drug response, facilitating the development and repositioning of cancer therapies for patients. The company's portfolio includes three lead drug candidates and an antibody-drug conjugate (ADC) program targeting 12 cancer indications, with one candidate in phase 2 clinical testing and two others recently entering phase 1 trials. Lantern Pharma employs a data-driven, biomarker-focused strategy to accelerate drug development while minimizing costs compared to traditional methods. Generated from the website